Huilin Huang
Chengqi Yi
Pengxu Qian
Hengyou Weng
Jianjun Chen- 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
- 2State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, China
- 3Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China
- 4Department of Chemical Biology, Synthetic and Functional Biomolecules Center, College of Chemistry and Molecular Engineering, Peking University, Beijing, China
- 5Center of Stem Cell and Regenerative Medicine, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- 6Liangzhu Laboratory, Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Zhejiang University Medical Center, Institute of Hematology, Zhejiang University, Hangzhou, China
- 7Guangzhou Laboratory, Guangzhou, China
- 8State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
- 9Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA, United States
- 10Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, CA, United States
Editorial on the Research Topic
Novel insights in RNA modifications: From basic to translational research
Introduction
Chemical modifications add to the diversity of biological macromolecules (e.g., DNA, RNA, and protein) and expand their molecular functions, and the aberrance of such modifications are found as one of the major causes of human diseases and aging (Flavahan et al., 2017; Cavalli and Heard, 2019; Yang et al., 2023). Due to the prominent roles of RNA modifications in human diseases such as cancer and the promise of targeting dysregulated RNA modification machineries in translational medicine (Huang et al., 2020a), the study of RNA modifications (e.g., m6A, m1A, m5C, m6Am, pseudouridine, and A-to-I editing) represents the new Frontier in the epigenetics field.
In this Research Topic on Novel Insights in RNA Modifications: from Basic to Translational Research, we aim to publish innovative research from basic science to translational research on RNA modifications. A total of 18 articles were included in this Research Topic, covering the novel methods to detect or modulate RNA modifications, the functions and mechanisms of RNA modifications in physiological processes (e.g., normal cellular functions, skeletal myogenesis and fetal development) and during pathogenesis (e.g., cancer, cadiomyopathy, lupus nephritis, inflammatory bowel disease and liver fibrosis), and the application of RNA modification in disease diagnostics and therapeutics. We summarize and discuss the main findings of these studies in this editorial.
Methodologies for measuring or modulating RNA modifications
The development of reliable m6A profiling methods, such as m6A-seq or MeRIP-seq, a method that uses antibodies to immunoprecipitate methylated RNAs for subsequent sequencing, greatly promotes our understanding of m6A. Recently developed antibody-free techniques, such as DART-seq (Meyer, 2019), m6A-SAC-seq (Hu et al., 2022) and GLORI (Liu et al., 2022), exhibit advantages over antibody-based methods, including requirement of less input RNA and eliminated/reduced cross-reactivity to other modifications, such as DNA 6 mA and RNA m6Am. In this Research Topic, Zhu et al. developed an improved version of in vitro DART-seq, which optimizes the APO1-YTH protein to achieve enhanced m6A recognition and allow for m6A mapping in any sample of interest using nanogram amounts of total RNA.
Programmable RNA modification is another powerful method for RNA modification study. Hundreds of m6A sites are often reprogrammed during physiological and pathological processes, making it difficult to dissect the phenotypic outcomes from a single m6A site. The advent of new CRISPR tools allow scientists to install or remove m6A modification at specific loci, showing promise in revealing the physiological or pathological effects of individual m6A mark, especially in vivo. In the review article, Lo et al. summarized recent findings on RNA editing and programmable RNA modification with CRISPR, base editors and non-CRISPR related tools, highlighting their future applications for basic and clinical research.
The functions and mechanisms of RNA methylations in physiological processes
Utilizing the m6A sequencing techniques, the profiling of m6A (also known as “epitranscriptome”) under various physiological context can be readily characterized, offering an opportunity for revealing the roles of m6A during these processes. Xie et al. characterized the expression and m6A methylation patterns of lncRNAs in mouse myoblasts and differentiated myotubes, uncovering a METTL3/m6A/Brip1os/Tbx2 Axis and the potential role of m6A on the temporal expression regulation of lncRNAs in skeletal myogenesis. Xiao et al. reported that maternal microbiome affects the m6A epitranscriptome of the mouse feral bran and intestine, probably by altering the expression of m6A writers and erasers, implying m6A might serve as a critical regulator for mediating the impact of microbiome to development and disease.
Besides development, RNA modifications have been reported to exert critical roles in a variety of physiological processes. With this regard, Wilkinson et al. summarized the functions and regulation of RNA modifications (e.g., m6A, m5C and m1A) in cellular processes, emphasizing the context-specific roles of RNA modifications during pathogenesis and the recent advances in disease prevention and therapy by targeting RNA modification.
The functions and mechanisms of RNA modifications during pathogenesis
The aberrant regulation and function of RNA modifications is pervasively found in human diseases, particularly in cancer. Huang et al. found m6A demethylase ALKBH5 serves as independent favorable prognostic marker and plays tumor suppressive function by modulating iron metabolism and epithelial-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma. Moreover, there are three Review articles in this Research Topic focusing on the roles of RNA modifications in cancer. Lu et al. summarized the interaction network of non-coding RNAs (ncRNAs) and their relationship with m6A modification in colorectal cancer (CRC). Gupta et al. focused on the functions of tRNAs, tRNA-derived stress-induced RNAs (tiRNAs) and tRNA-derived fragments (tRFs), as well as their modifications, during tumor development and progression. Liu et al. reviewed recent findings of several common RNA modifications on mRNAs, rRNAs and tRNAs and their regulators in breast cancer.
Besides, RNA modifications emerge as key players in other chronic disease and injury. Yu et al. reported FTO, another m6A demethylase, played a role in hyperlipidemia-induced cardiomyopathy. A novel compound, known as LuHui Derivative, could inhibit FTO and alleviate the inflammatory response and injury in hyperlipidemia-induced cardiomyopathy. Fan et al. revealed the involvement of m6A methylation and its regulator in the development of liver fibrosis, a chronic liver injury that may lead to cirrhosis and even liver cancer, through performing m6A-seq and RNA-seq in liver fibrosis mice. Zhao et al. analyzed the expression of m6A regulators in the glomeruli in lupus nephritis compared with tubulointerstitium and whole kidney tissue, and established an m6A regulator signature that can distinguish lupus nephritis and healthy individuals. Nie et al. found m6A regulators displayed extensive differential expression in the cohorts of inflammatory bowel disease, in which two clusters of consensus clustering exhibit different immune phenotypes and clinical characteristics. These research provide insights that m6A methylation may be associated with the occurrence of these diseases; however, further studies are needed to determine its role.
The application of RNA modifications in translational medicine
It has been anticipated that RNA modifications, similar to DNA methylation, could serve as biomarkers for clinical diagnostics. The integrative analyses by Xu et al. and Gu et al. suggested that m6A regulators may represent promising biomarkers for prediction of prognosis and clinical responses to targeted or immune therapy of low-grade glioma and HCC patients. Katanski et al. performed multiplex small RNA sequencing (MSR-seq) on residual nasopharyngeal swabs to test the idea of utilizing host tRNA properties as biomarkers for the clinical outcome of SARS-CoV-2. They reported that combining tRNA modifications with full-length tRNA abundance and tRNA fragmentation could provide strong power for the accurate prediction of SARS-CoV-2 infection symposium severity, shedding light on the application of tRNA modification and also potentially other RNA modifications as diagnostic biomarkers.
In clinical practice, RNA modification has become a powerful tool in making mRNA vaccines. Morais et al. reviewed the effect and mechanism of N1-methyl-pseudouridine in the successful invention of mRNA vaccines against SARS-CoV-2. From a broader view, Liu et al. summarized the roles of cap and tail modifications, nucleoside substitutes, and chimeric mRNAs on tuning the properties of mRNAs and discussed the potential of harnessing the efficacy of mRNA drugs through such mRNA modifications.
Conclusion
The studies published in this Research Topic provide a window into the basic and translational research of RNA modifications. We hope the studies and insight provided by the research and review articles in this Research Topic could inspire researchers and bring critical thinking on the field of epitranscriptomics.
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Funding
This work was supported by the National Key Research and Development Program of China (2020YFA0112403 to HW, 2019YFA0110900 and 2019YFA0802200 to CY, 2022YFA1103500 and 2018YFA0109300 to PQ), the National Natural Science Foundation of China (82173058 to HH, 82270168 to HW, 21825701 and 92153303 to CY, 82222003, 92268117 and 82161138028 to PQ), the U.S. National Institutes of Health (NIH) grants (R01 CA243386 and R01 CA271497 to JC), Guangdong Basic and Applied Basic Research Foundation (2021A1515010425 to HH), the Zhejiang Provincial Natural Science Foundation of China (LR19H080001 to PQ), the Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2020R01006 to PQ) and the Guangdong Research Program (2021ZT09Y233 to HW).
Acknowledgments
We would like to express our sincere thanks to the guest editorial team and all the reviewers who participated in the peer-review process of this Research Topic. At the same time, we would like to thank all the authors who contributed to this Research Topic.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Cavalli, G., and Heard, E. (2019). Advances in epigenetics link genetics to the environment and disease. Nature 571, 489–499. doi:10.1038/s41586-019-1411-0
Flavahan, W. A., Gaskell, E., and Bernstein, B. E. (2017). Epigenetic plasticity and the hallmarks of cancer. Science 357, eaal2380. doi:10.1126/science.aal2380
Hu, L., Liu, S., Peng, Y., Ge, R., Senevirathne, C., Harada, B. T., et al. (2022). m6A RNA modifications are measured at single-base resolution across the mammalian transcriptome. Nat. Biotechnol. 40, 1210–1219. doi:10.1038/s41587-022-01243-z
Huang, H. L., Weng, H. Y., Deng, X. L., and Chen, J. J. (2020). RNA modifications in cancer: Functions, mechanisms, and therapeutic implications. Annu. Rev. Canc Biol. 4, 221–240. doi:10.1146/annurev-cancerbio-030419-033357
Huang, H., Weng, H., and Chen, J. (2020). m6A modification in coding and non-coding RNAs: Roles and therapeutic implications in cancer. Cancer Cell. 37, 270–288. doi:10.1016/j.ccell.2020.02.004
Liu, C., Sun, H., Yi, Y., Shen, W., Li, K., Xiao, Y., et al. (2022). Absolute quantification of single-base m6A methylation in the mammalian transcriptome using GLORI. Nat. Biotechnol. doi:10.1038/s41587-022-01487-9
Meyer, K. D. (2019). DART-Seq: An antibody-free method for global m6A detection. Nat. Methods 16, 1275–1280. doi:10.1038/s41592-019-0570-0
Keywords: M6A, epitranscriptome, RNA editing, development, cancer, biomarker, RNA vaccine
Citation: Huang H, Yi C, Qian P, Weng H and Chen J (2023) Editorial: Novel insights in RNA modifications: From basic to translational research. Front. Cell Dev. Biol. 11:1155993. doi: 10.3389/fcell.2023.1155993
Received: 01 February 2023; Accepted: 14 February 2023;
Published: 22 February 2023.
Edited and reviewed by:
Michael E. Symonds, University of Nottingham, United KingdomCopyright © 2023 Huang, Yi, Qian, Weng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Huilin Huang, aHVhbmdobDFAc3lzdWNjLm9yZy5jbg==; Chengqi Yi, Y2hlbmdxaS55aUBwa3UuZWR1LmNu; Pengxu Qian, YXh1QHpqdS5lZHUuY24=; Hengyou Weng, d2VuZ19oZW5neW91QGd6bGFiLmFjLmNu; Jianjun Chen, amlhbmNoZW5AY29oLm9yZw==